Descrição
Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.
First Treatment for Agitation Associated With Alzheimer Disease
Alzheimer's Disease Insight Report: Current Therapies, Drug
FDA approves new drug for Alzheimer's-Associated agitation
Decision on Brexpiprazole for Alzheimer's Agitation Due in May
Drugs Archives - Alzheimer's & Dementia Weekly
FDA Approves the First Drug for Alzheimer's Agitation: Rexulti
First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for
Lundbeck: Alzheimer's agitation drug can make a real difference
New Alzheimer's Disease Drugs
Speaking Alzheimer's: A Glossary of Common Terms
FDA advisory committee vote in favor of Lundbeck and Otsuka's
de
por adulto (o preço varia de acordo com o tamanho do grupo)
